

09/885,259

- 2 -

PC18174A

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-33. (canceled).

34. (currently amended) A method of treating rheumatoid arthritis in a mammal comprising administering to said mammal a therapeutically effective amount of an antibody to a M-CSF that is effective to treat said rheumatoid arthritis, wherein said antibody inhibits the synergistic effect of M-CSF on MCP-1 mediated monocyte shape change.

35. (canceled).

36. (previously presented) The method of claim 34 wherein said antibody is a monoclonal antibody.

37-47. (canceled).

48. (previously presented) The method of claim 34, wherein said M-CSF is a human M-CSF.

49. (previously presented) The method of claim 36, wherein said M-CSF is a human M-CSF.

50. (currently amended) A method of treating rheumatoid arthritis in a mammal comprising administering to said mammal a therapeutically effective amount of an antibody to a human M-CSF that is effective to treat said rheumatoid arthritis, wherein said antibody inhibits the synergistic effect of M-CSF on MCP-1 mediated monocyte shape change.

51. (currently amended) A method of treating rheumatoid arthritis in a human comprising administering to said human a therapeutically effective amount of a monoclonal antibody to a human M-CSF that is effective to treat said rheumatoid arthritis, wherein said antibody inhibits the synergistic effect of M-CSF on MCP-1 mediated monocyte shape change.

09/885,259

- 3 -

PC18174A

52. (currently amended) A method of treating rheumatoid arthritis in a human comprising administering to said human a therapeutically effective amount of a monoclonal antibody to a M-CSF, wherein said antibody inhibits the synergistic effect of M-CSF on MCP-1 mediated monocyte shape change.

53. (New) A method of treating rheumatoid arthritis in a human comprising administering to said human a therapeutically effective amount of a monoclonal human antibody to a human M-CSF, wherein said antibody inhibits the synergistic effect of M-CSF on MCP-1 mediated monocyte shape change.